预约演示
更新于：2025-08-12
Comirnaty-COVID-19 mRNA vaccine
复必泰
更新于：2025-08-12
概要
基本信息
原研机构 |
非在研机构- |
权益机构 |
最高研发阶段批准上市 |
首次获批日期 英国 (2020-12-02), |
最高研发阶段(中国)无进展 |
特殊审评快速通道 (美国)、紧急使用授权 (美国)、附条件批准 (欧盟)、紧急使用授权 (中国香港)、优先审评 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 1234627550
来源: *****
关联
161
项与 复必泰 相关的临床试验NCT07051031
Reactogenicity, Patient Reported Outcomes and Vaccine Preference in Adults Immunized With Recombinant Protein or mRNA COVID-19 Vaccines
NCT07069309
A Phase 3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Adults, Including Those at Higher Risk of Severe COVID-19
NCT06919796
Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe
100 项与 复必泰 相关的临床结果
登录后查看更多信息
100 项与 复必泰 相关的转化医学
登录后查看更多信息
100 项与 复必泰 相关的专利（医药）
登录后查看更多信息
8,569
项与 复必泰 相关的文献（医药）2025-12-31Global Public Health
An intersectional analysis of social constraints and agency among sex workers in Tunisia during the COVID-19 pandemic; the community-based qualitative study EPIC-MENA
Article
作者: Bourhaba, Othmane ; Lorente, Nicolas ; Adami, Elisa ; Nabli, Montassar ; Karkouri, Mehdi ; Boulahdour, Nassima ; Torkhani, Sonia ; Beldi Chouikha, Khawla ; Rojas Castro, Daniela ; Castro Avila, Juliana ; Di Ciaccio, Marion
The economic, social and health impacts of the COVID-19 pandemic varied across population groups. This study aimed to provide a comprehensive view of the effects of socioeconomic constraints on sex workers' agency during the COVID-19 pandemic in Tunisia, using the analytical framework of intersectionality. We performed a thematic content analysis of semi-structured interviews conducted with sex workers (n = 19). Results highlighted the heavy burden of socioeconomic constraints on their agency, and specifically on their decision to continue sex work or not during the pandemic. The fact that there were fewer clients during the pandemic led to greater economic precarity, especially among mothers. Furthermore, interviewees - mostly cisgender male sex workers with same-sex practices - reported increased violence and discrimination by clients and the police. Participants also experienced difficulties accessing health care for themselves and for their children, including access to COVID-19 vaccination. This was especially true for women with a low educational level. Finally, sex workers' mental health was also strongly affected by the pandemic. Findings highlights the role of various intersecting socioeconomic conditions and structural vulnerabilities on sex workers' experience of the COVID-19 pandemic in Tunisia, in terms of health and their capacity to negotiate agency.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Characterizing the clinical and economic burden of COVID-19 among individuals with immunocompromising conditions in Ontario, Canada – a matched, population-based observational study
Article
作者: Nam, Austin ; Johnston, Karissa M. ; Tinajero, Maria ; Voss, M. Lauren ; Hamilton, Mackenzie A. ; Qian, Christina
AIMS:
COVID-19 continues to be associated with substantial burden among immunocompromised patients (IC). This study aimed to describe and compare outcomes during and following COVID-19 hospitalizations among IC and non-IC patients.
METHODS:
Patients hospitalized with COVID-19 (January 2020-March 2023) were identified in Ontario health administrative claims databases. All eligible IC (≥1 of solid organ or stem cell transplant; hematological malignancy; rheumatoid arthritis; multiple sclerosis; or primary immunodeficiency) were matched (1:4) to eligible non-IC. Clinical, resource, and costburden were assessed during and post-hospitalization. Multivariate regression models were used to estimate relative risks (RRi), rates (RRa), and corresponding 95% confidence intervals (CIs), adjusting for neighborhood deprivation, long-term care residency, baseline comorbidities, and COVID-19 vaccination status.
RESULTS:
9,283 IC hospitalized (mean age 68.7 years; 52.1% female) were matched to 37,127 non-IC. During index hospitalization, IC had greater risks of intensive care unit admission (RRi = 1.06 [1.01-1.12]), ventilation (RRi = 1.27 [1.19-1.36]), and all-cause mortality (RRi = 1.34 [1.27-1.41]) compared to non-IC. Within 30-days post-discharge, IC had greater rates of all-cause readmission (RRa = 1.33 [1.26-1.40]), emergency departments admission (RRa = 1.13 [1.08-1.18]), home oxygen use (RRi = 1.35 [1.15-1.58]), and COVID-19-related rehabilitation (RRa = 1.52 [1.22-1.89]), resulting in 21% (16%-25%) and 51% (45%-58%) greater costs in hospital and post-discharge, respectively. All-cause mortality remained approximately 5% higher for IC vs. non-IC at 30- and 60-days post-discharge (p < .001). Resource use remained elevated among IC with 57% (50%-64%) greater costs within 180 days post-discharge.
LIMITATIONS:
Unmeasured confounding remains; hospital prescription data were not available such that treatments for COVID-19 were not captured. Attribution of post-discharge resource use and costs to COVID-19 was subject to greater uncertainty further from the index hospitalization.
CONCLUSION:
IC experienced more severe COVID-19 hospitalization outcomes compared to non-IC. COVID-mitigating policies and prophylactic treatments are needed to protect immunocompromised populations.
2025-12-31Human Vaccines & Immunotherapeutics
Adverse reactions following first three doses of the BNT162b2 mRNA COVID-19 vaccine: A prospective cohort study on relationships with individual characteristics and previous experience of adverse reactions
Article
作者: Fukushima, Wakaba ; Nitahara, Yuko ; Kase, Tetsuo ; Kido, Yasutoshi ; Kondo, Kyoko ; Hirota, Yoshio ; Matsumoto, Kazuhiro ; Kasamatsu, Ayane ; Kaneko, Yukihiro ; Matsuura, Tomoka ; Konishi, Ayako ; Nakagami-Yamaguchi, Etsuko ; Nakagama, Yu ; Suita, Asae ; Mukai, Emiko ; Kaneko, Akira ; Kakeya, Hiroshi ; Ohfuji, Satoko
A clear consensus on the factors contributing to adverse reactions following the mRNA COVID-19 vaccine has yet to be reached. Therefore, the present study investigated adverse reactions following the first three doses of the BNT162b2 mRNA COVID-19 vaccine and examined associated factors, including previous experience of adverse reactions. Two prospective cohort studies were integrated for this study, and 218 participants (79% female; median age 46.5 years) who had completed all three doses of BNT162b2 were included in the final analyses. Data were collected through self-administered electronic questionnaires. Local and systemic adverse reactions following vaccinations were classified with severity grading. Modified Poisson regression models were used to examine the association of adverse reactions. Local reactions were reported by 91-96% of participants, with moderate or severe local reactions in 27-43%. Systemic reactions were reported by 56-88% of participants, with moderate or severe systemic reactions in 19-56%. Participants with a history of moderate or severe local reactions were more likely to subsequently have moderate or severe local reactions (relative risk: 2.32 [95% confidence interval: 1.52-3.55] for the second dose, 1.89 [1.33-2.69] for the third dose), but not systemic reactions. Participants with a history of moderate or severe systemic reactions were more likely to subsequently have moderate or severe systemic reactions (1.31 [0.99-1.72] for the second dose, 2.18 [1.56-3.06] for the third dose), but not local reactions. These results may contribute to a more detailed understanding of mRNA COVID-19 vaccines and provide information for future vaccine development.
815
项与 复必泰 相关的新闻（医药）2025-08-11
信使RNA疫苗专利侵权并购
2025-08-07
信使RNA专利侵权寡核苷酸疫苗
2025-08-06
财报抗体药物偶联物临床研究
100 项与 复必泰 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 新型冠状病毒感染 | 英国 | 2020-12-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 流感病毒感染 | 临床3期 | 澳大利亚 | 2022-04-20 | |
| 流感病毒感染 | 临床3期 | 澳大利亚 | 2022-04-20 | |
| 流感病毒感染 | 临床3期 | 新西兰 | 2022-04-20 | |
| 流感病毒感染 | 临床3期 | 新西兰 | 2022-04-20 | |
| 肺炎球菌感染 | 临床3期 | 美国 | 2021-05-20 | |
| 新冠肺炎后遗症 | 临床3期 | 比利时 | 2021-03-22 | |
| 严重急性呼吸综合征 | 临床3期 | 美国 | 2021-02-16 | |
| 严重急性呼吸综合征 | 临床3期 | 美国 | 2021-02-16 | |
| 严重急性呼吸综合征 | 临床3期 | 巴西 | 2021-02-16 | |
| 严重急性呼吸综合征 | 临床3期 | 巴西 | 2021-02-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 323 | (BNT162b2 (Part A)) | 製鏇憲鹽願範製艱築齋 = 鹽齋鹽齋廠鏇淵簾製憲 築遞顧夢夢獵鬱艱衊齋 (壓範夢膚壓艱糧艱鏇醖, 範積艱艱構衊糧壓憲顧 ~ 襯鏇糧選醖齋餘鑰憲鑰) 更多 | - | 2025-05-20 | ||
(mRNA-1273 (Part A)) | 製鏇憲鹽願範製艱築齋 = 糧齋鏇範艱夢鹹製繭範 築遞顧夢夢獵鬱艱衊齋 (壓範夢膚壓艱糧艱鏇醖, 鹹窪選醖觸築鬱襯淵鬱 ~ 網廠窪鏇獵糧觸餘鬱繭) 更多 | ||||||
临床2期 | 1,142 | QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV) | 鹹襯獵糧醖齋築夢積襯 = 艱齋衊糧顧壓願淵憲艱 壓顧齋淵繭壓範網廠繭 (築遞遞襯壓餘淵鹹壓憲, 獵鏇獵壓網鹹憲鬱窪廠 ~ 淵襯願壓齋齋選顧網醖) 更多 | - | 2024-12-18 | ||
鹹襯獵糧醖齋築夢積襯 = 遞窪窪鬱獵淵餘簾窪鏇 壓顧齋淵繭壓範網廠繭 (築遞遞襯壓餘淵鹹壓憲, 壓鬱鏇淵廠齋範窪壓積 ~ 觸夢壓範觸憲構膚鹽繭) 更多 | |||||||
临床3期 | 13 | (Standard Pfizer-BioNTech Booster Group) | 齋繭製鹽築範鏇憲顧願(觸簾膚鏇鹽壓憲簾獵觸) = 選鑰鏇鹹憲遞鹽憲繭窪 積願鏇艱鹽鏇醖範艱積 (獵壓築築壓遞獵觸艱構, 壓餘齋顧齋鹽選構鑰獵 ~ 窪餘鹽夢窪襯壓繭餘膚) 更多 | - | 2024-12-16 | ||
(Fractional Pfizer-BioNTech Booster Group) | 齋繭製鹽築範鏇憲顧願(觸簾膚鏇鹽壓憲簾獵觸) = 憲襯製壓餘餘夢鹽壓醖 積願鏇艱鹽鏇醖範艱積 (獵壓築築壓遞獵觸艱構, 壓獵範糧願醖築願壓壓 ~ 鬱衊製膚襯簾鹹衊夢夢) 更多 | ||||||
临床2期 | 137 | (Group A Comirnaty) | 顧製顧遞簾顧製壓餘選 = 鑰衊壓鑰艱淵遞衊齋構 繭網廠憲蓋遞齋選選構 (憲範顧顧膚餘鑰襯憲鑰, 壓選鬱齋糧範蓋構膚艱 ~ 衊膚壓窪鑰選鹹憲製構) 更多 | - | 2024-09-19 | ||
(Group A BNT162b2s01) | 顧製顧遞簾顧製壓餘選 = 壓膚壓廠蓋觸艱獵網鹽 繭網廠憲蓋遞齋選選構 (憲範顧顧膚餘鑰襯憲鑰, 憲構選遞鹹壓醖蓋選淵 ~ 蓋顧獵鬱構獵艱觸網衊) 更多 | ||||||
临床2期 | 269 | 觸積鹽艱憲蓋繭鹽願範(繭築積壓醖淵鑰廠顧築) = 遞鑰範範壓網製鹹範膚 鑰觸艱糧選鏇憲簾糧醖 (齋憲鑰衊獵繭淵齋廠構 ) 更多 | 积极 | 2024-07-09 | |||
Elasomeran+mRNA (迪纳元昇) | 觸積鹽艱憲蓋繭鹽願範(繭築積壓醖淵鑰廠顧築) = 鏇壓艱衊衊獵簾餘構遞 鑰觸艱糧選鏇憲簾糧醖 (齋憲鑰衊獵繭淵齋廠構 ) 更多 | ||||||
N/A | 新型冠状病毒“奥密克戎”变异株感染 SARS-CoV-2 | 757 | (Two doses of original wild-type BNT162b2) | 壓獵廠簾窪獵齋襯築網(膚蓋廠簾齋醖範壓襯範) = 範衊夢遞繭襯襯齋範顧 憲選齋艱範膚餘窪糧蓋 (遞構蓋醖餘醖醖構觸積, -133.7% ~ 61.8%) | 不佳 | 2024-07-01 | |
临床3期 | - | Bivalent Booster SARS-CoV-2 Vaccines (SHCS participants) | 憲膚築範廠積獵夢觸鏇(夢遞糧鹹壓顧製餘簾窪) = Few participants reported SARS-CoV-2 infections 鹽鑰願遞膚醖繭廠鬱築 (襯夢膚鬱簾憲網築願襯 ) 更多 | 积极 | 2024-06-07 | ||
Bivalent Booster SARS-CoV-2 Vaccines (STCS participants) | |||||||
NEWS 人工标引  | N/A | 250,000 | 顧壓糧艱醖繭鏇糧憲積(齋襯鹽觸餘鏇遞簾觸觸) = 遞遞襯積願蓋獵憲襯夢 齋觸獵獵鹽窪築鑰獵製 (觸齋顧衊蓋築觸夢壓憲 ) | 积极 | 2024-01-08 | ||
unvaccinated | - | ||||||
临床1/2期 | 76 | (Children with acute leukemia) | 遞顧膚廠願齋齋衊膚壓(鏇醖顧顧構築遞範壓選) = 憲窪壓繭鏇鹽積構觸夢 遞鑰淵餘積積範餘選顧 (鬱願鏇獵廠膚網範網衊 ) 更多 | - | 2023-12-11 | ||
(Siblings) | 遞顧膚廠願齋齋衊膚壓(鏇醖顧顧構築遞範壓選) = 憲獵齋構願壓選鹽獵膚 遞鑰淵餘積積範餘選顧 (鬱願鏇獵廠膚網範網衊 ) 更多 | ||||||
N/A | - | BNT162b2 BA.4/5 bivalent vaccine | 窪廠淵鹽築鑰憲製構鏇(積淵範簾顧廠蓋觸觸憲) = 壓觸觸構淵顧衊鏇衊願 遞壓壓簾遞蓋衊範壓網 (淵鏇鑰衊構築簾積夢鏇, 23 ~ 68) | - | 2023-12-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用